Previous close | 64.95 |
Open | 64.95 |
Bid | 65.07 x 100 |
Ask | 65.64 x 100 |
Day's range | 64.68 - 65.60 |
52-week range | 37.06 - 70.81 |
Volume | |
Avg. volume | 145,382 |
Market cap | 1.371B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 76.86 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.